We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+27.37%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$563M
AUM Growth
+$52.1M
Cap. Flow
-$54.1M
Cap. Flow %
-9.6%
Top 10 Hldgs %
49.74%
Holding
65
New
13
Increased
15
Reduced
18
Closed
8

Top Buys

Rank Stock Value
1
NUVA
NuVasive, Inc.
NUVA
+$7.38M
2
ACGN
Aceragen Inc
ACGN
+$6.67M
3
SPNC
Spectranetics Corp
SPNC
+$6.23M
4
TXMD icon
TherapeuticsMD
TXMD
+$5.15M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$4.96M

Top Sells

Rank Stock Value
1
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$28.6M
2
IART icon
Integra LifeSciences
IART
+$11.1M
3
IPXL
Impax Laboratories, Inc.
IPXL
+$9.83M
4
ARTC
ARTHROCARE CORP
ARTC
+$9.17M
5
HITK
HI-TECH PHARMACAL INC
HITK
+$9.07M

Sector Composition

Rank Sector Weight
1 Healthcare 77.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASRT
1
DELISTED
Assertio
ASRT
$42M 7.46%
93,700
– –
ANGO icon
2
AngioDynamics
ANGO
$566M
$37.3M 6.62%
2,826,651
+100,000
+4% +$1.18M
NTUS
3
DELISTED
Natus Medical Inc
NTUS
$35.7M 6.35%
2,520,992
-70,000
-3% -$936K
LCI
4
DELISTED
Lannett Company, Inc.
LCI
$28.6M 5.07%
327,140
-128,425
-28% -$7.51M
NVDQ
5
DELISTED
Novadaq Technologies Inc.
NVDQ
$27.9M 4.95%
1,687,090
-296,352
-15% -$4.21M
AVDL
6
DELISTED
Avadel Pharmaceuticals
AVDL
$24.7M 4.39%
3,767,911
+628,780
+20% +$3.87M
TEVA icon
7
Teva Pharmaceuticals
TEVA
$36.4B
$24.2M 4.3%
641,736
-221,500
-26% -$8.64M
EBS icon
8
Emergent Biosolutions
EBS
$393M
$20.5M 3.63%
1,074,248
– –
TTPH
9
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$20.4M 3.62%
89,666
+18,250
+26% +$3.19M
IPXL
10
DELISTED
Impax Laboratories, Inc.
IPXL
$18.9M 3.35%
922,543
-476,000
-34% -$9.83M
ANAC
11
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$18.5M 3.28%
1,737,669
+13,641
+0.8% +$119K
PGNX
12
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$17.5M 3.1%
3,479,348
-21,267
-0.6% -$115K
CEMP
13
DELISTED
Cempra, Inc.
CEMP
$16M 2.84%
1,391,357
-163,790
-11% -$1.44M
ALKS icon
14
Alkermes
ALKS
$8.69B
$15.1M 2.69%
450,000
-150,000
-25% -$4.88M
AUXL
15
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$14.8M 2.62%
811,100
+11,100
+1% +$201K
NPSP
16
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$14.4M 2.55%
451,597
-1,245,157
-73% -$28.6M
RIGL icon
17
Rigel Pharmaceuticals
RIGL
$747M
$12.8M 2.27%
356,582
+51,582
+17% +$1.88M
BDSI
18
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$11.5M 2.05%
2,122,054
– –
DSCI
19
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$9.55M 1.7%
771,598
-3,402
-0.4% -$47K
IART icon
20
Integra LifeSciences
IART
$1.49B
$8.91M 1.58%
541,627
-688,738
-56% -$11.1M
SPNC
21
DELISTED
Spectranetics Corp
SPNC
$8.33M 1.48%
495,833
+357,113
+257% +$6.23M
ACGN
22
DELISTED
Aceragen Inc
ACGN
$7.87M 1.4%
+33,305
New +$6.67M
DRRX
23
DELISTED
DURECT Corp
DRRX
$7.55M 1.34%
563,298
-36,612
-6% -$434K
ATRC icon
24
AtriCure
ATRC
$1.79B
$7.44M 1.32%
677,543
-114,298
-14% -$1.13M
NUVA
25
DELISTED
NuVasive, Inc.
NUVA
$7.35M 1.3%
+300,000
New +$7.38M
1
2 3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q3 2013 Portfolio in Review

As of Q3 2013, Broadfin Capital held 65 positions worth $563M, up 10% from $511M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Broadfin Capital withdrew a net $54.1M in Q3 2013, closing 8 positions and reducing 18 holdings. Its most notable exit was ARTHROCARE CORP, an estimated $9.17M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 73% a quarter earlier.

Against the trend, Broadfin Capital opened a new position in NuVasive, Inc. worth $7.35M.

  • Broadfin Capital's largest Q3 2013 buy was NuVasive, Inc.: 300,000 shares worth $7.35M.
  • Broadfin Capital added most to Spectranetics Corp in Q3 2013, an estimated $6.23M increase.
  • Broadfin Capital's biggest Q3 2013 reduction was NPS PHARMACEUTICALS INC, cutting an estimated $28.6M.
  • Broadfin Capital fully exited ARTHROCARE CORP in Q3 2013, selling an estimated $9.17M.
  • Broadfin Capital's ten largest holdings make up 50% of its $563M portfolio in Q3 2013.
  • Broadfin Capital opened 13 new positions and closed 8 in Q3 2013.
  • Broadfin Capital's portfolio value rose 10% quarter-over-quarter to $563M.

Based on Broadfin Capital's 13F filing for Q3 2013, filed 14 Nov 2013.